AU2021224990B2 - Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids - Google Patents

Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Info

Publication number
AU2021224990B2
AU2021224990B2 AU2021224990A AU2021224990A AU2021224990B2 AU 2021224990 B2 AU2021224990 B2 AU 2021224990B2 AU 2021224990 A AU2021224990 A AU 2021224990A AU 2021224990 A AU2021224990 A AU 2021224990A AU 2021224990 B2 AU2021224990 B2 AU 2021224990B2
Authority
AU
Australia
Prior art keywords
mirna
cells
mrna
composition
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021224990A
Other languages
English (en)
Other versions
AU2021224990A1 (en
Inventor
Valerie DUVAL
Romain MICOL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Combined Therapeutics Inc
Original Assignee
Combined Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combined Therapeutics Inc filed Critical Combined Therapeutics Inc
Publication of AU2021224990A1 publication Critical patent/AU2021224990A1/en
Application granted granted Critical
Publication of AU2021224990B2 publication Critical patent/AU2021224990B2/en
Priority to AU2025271119A priority Critical patent/AU2025271119A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2021224990A 2020-02-21 2021-02-22 Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids Active AU2021224990B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025271119A AU2025271119A1 (en) 2020-02-21 2025-11-21 Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062979619P 2020-02-21 2020-02-21
US62/979,619 2020-02-21
US202063059458P 2020-07-31 2020-07-31
US63/059,458 2020-07-31
PCT/US2021/019028 WO2021168405A1 (en) 2020-02-21 2021-02-22 Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025271119A Division AU2025271119A1 (en) 2020-02-21 2025-11-21 Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Publications (2)

Publication Number Publication Date
AU2021224990A1 AU2021224990A1 (en) 2022-09-15
AU2021224990B2 true AU2021224990B2 (en) 2025-08-28

Family

ID=77391786

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021224990A Active AU2021224990B2 (en) 2020-02-21 2021-02-22 Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
AU2025271119A Pending AU2025271119A1 (en) 2020-02-21 2025-11-21 Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025271119A Pending AU2025271119A1 (en) 2020-02-21 2025-11-21 Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Country Status (11)

Country Link
US (4) US11596685B2 (https=)
EP (1) EP4106770A4 (https=)
JP (1) JP7539723B2 (https=)
KR (2) KR102838785B1 (https=)
CN (1) CN115297868B (https=)
AU (2) AU2021224990B2 (https=)
CA (1) CA3168048A1 (https=)
IL (1) IL295724A (https=)
MX (1) MX2022010084A (https=)
WO (1) WO2021168405A1 (https=)
ZA (1) ZA202208795B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
EP4065600A1 (en) 2019-11-25 2022-10-05 Cornell University Apoe gene therapy
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
MX2023001187A (es) * 2020-07-31 2023-04-04 Combined Therapeutics Inc Composiciones y métodos para una vacunación mejorada.
CN116445492A (zh) * 2022-01-10 2023-07-18 北京锦篮基因科技有限公司 用于x染色体连锁肾上腺脑白质营养不良的基因治疗药物和方法
CN114874999B (zh) * 2022-04-22 2023-04-21 中国医学科学院病原生物学研究所 一种基于痘苗病毒载体的新型冠状病毒病毒样颗粒疫苗
CN116004628B (zh) * 2023-01-03 2024-07-19 苏州大学 一种预防或治疗慢性疼痛的miRNA靶点及其应用
CN117530932B (zh) * 2024-01-08 2024-04-26 中国药科大学 一种抑制肿瘤生长及肺转移的人工外泌体及其应用
WO2025251079A1 (en) * 2024-05-31 2025-12-04 University Of Massachusetts Rna compositions and methods of use thereof in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019158955A1 (en) * 2018-02-19 2019-08-22 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
US7993831B2 (en) * 2007-09-14 2011-08-09 Asuragen, Inc. Methods of normalization in microRNA detection assays
WO2010126766A1 (en) * 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
CN108474003A (zh) 2015-11-20 2018-08-31 俄勒冈健康与科学大学 包含微小rna识别元件的cmv载体
SI3458083T1 (sl) * 2016-05-18 2023-03-31 Modernatx, Inc. Polinukleotidi, ki kodirajo interlevkin-12 (IL12) in njihova uporaba
CN110402145A (zh) * 2016-10-26 2019-11-01 莫得纳特斯公司 用于增强免疫应答的信使核糖核酸及其使用方法
WO2018115527A2 (en) * 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
GB201714430D0 (en) 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
EP3986447A4 (en) * 2019-06-18 2023-08-16 Citranvi Biosciences, LLC RATIONALLY MANIPULATED CARRIER PROTEINS FOR VACCINES
GB2594683A (en) * 2020-02-17 2021-11-10 Vaxbio Ltd Vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019158955A1 (en) * 2018-02-19 2019-08-22 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BROWN B D ET AL: "Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications", NATURE REVIEWS GENETICS, MACMILLAN MAGAZINES, GB, vol. 10, no. 8, 1 August 2009 (2009-08-01), pages 578 - 585, XP002607892 *

Also Published As

Publication number Publication date
US20230241206A1 (en) 2023-08-03
US11931409B2 (en) 2024-03-19
JP2023514594A (ja) 2023-04-06
US11596685B2 (en) 2023-03-07
ZA202208795B (en) 2023-11-29
IL295724A (en) 2022-10-01
WO2021168405A1 (en) 2021-08-26
EP4106770A4 (en) 2024-05-15
KR20250114450A (ko) 2025-07-29
EP4106770A1 (en) 2022-12-28
AU2025271119A1 (en) 2025-12-18
US20240252618A1 (en) 2024-08-01
MX2022010084A (es) 2022-12-07
US20220202932A1 (en) 2022-06-30
KR20220144831A (ko) 2022-10-27
KR102838785B1 (ko) 2025-07-28
AU2021224990A1 (en) 2022-09-15
JP7539723B2 (ja) 2024-08-26
US12220456B2 (en) 2025-02-11
CN115297868B (zh) 2024-04-12
US20250170233A1 (en) 2025-05-29
CN115297868A (zh) 2022-11-04
CA3168048A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
AU2021224990B2 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
US12195746B2 (en) Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue
US20200376142A1 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
HK40083636B (zh) 用於编码核糖核酸的器官保护性表达和调节的组合物及方法
HK40083636A (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
AU2026201221A1 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
HK40022397B (en) Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue
HK40022397A (en) Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue
Aitken Blocking the RNA interference pathway improves oncolytic virus therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)